Combination Treatment for Moderate to Severe Acne

To determine if a combination of three currently approved acne products are safe and effective for the treatment of moderate to severe acne

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acne Acne Vulgaris Acneiform Eruptions Sebaceous Gland Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

12 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Birmingham, Alabama, United States

About this study

A Phase IV, Open-Label Study Evaluating the treatment for Combination Acne Therapy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

moderate to severe acne, IGA = 3 or 4 (Investigator Global Assessment)

Exclusion criteria

pregnancy and allergies

Treatment and study plan

Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide

Drug

Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night

Primary outcomes

Proportion of patients showing improvement from Baseline and Week 12

Time frame: Week 12

Sponsors and collaborators

Lead sponsor

Medicis Global Service Corporation

Industry

Registry information

Official study title

A Phase IV, Open-Label Study Evaluating the Use of Solodyn (Minocycline HCL Extended-Release Tablets), Ziana, and Triaz Foaming Cloths as Combination Acne Therapy Prior to Treatment With Isotretinoin

Important dates

Study start: 2010
Primary completion: 2011
Study completion: 2011
First posted: Sep 21, 2010
Registry last updated: Nov 30, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed